Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Asia-Pacific: Five largest Equity Offering deals by value in the Pharmaceuticals sector (LTM June 2022)

  • A total of 95 Equity Offering deals (pending and completed) were announced in the Pharmaceuticals of the Asia-Pacific region, in the last twelve months resulting in a total deal value of over $18,899.8 million. In the LTM period, December 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $5,471.7 million, resulting in an average deal value of $420.9 million during that month. On the other hand, the month of November 2021 was the most prolific in terms of deal volume, recording a total of 14 deals, resulting in an average deal value of $326.0 million during that month.

  • Of the 95 deals, the deal secured between Sino Biopharmaceutical Ltd; Yifan Pharmaceutical Co Ltd and Yiyi Biopharmaceutical (Beijing) Co., Ltd., was the largest Equity Offering deal in the Asia-Pacific Pharmaceuticals sector, which was valued at $70.0 million and was completed on June 2, 2022. The second-largest deal was between Innovent Biologics Inc and Ascentage Pharma Group International, while the third-largest deal was between Asset One Asset Management Co Ltd; Company K Partners Limited; IBK Securities Co. Ltd.; Meritz Securities Co Ltd and KoBioLabs Inc. The Innovent Biologics Inc-Ascentage Pharma Group International deal and the Asset One Asset Management Co Ltd; Company K Partners Limited; IBK Securities Co. Ltd.; Meritz Securities Co Ltd-KoBioLabs Inc deal were valued at $50.0 million and $28.5 million, respectively. The fourth-largest deal was between Changsha Xingchen Kangrui Venture Capital Partnership Enterprise; Hunan Fangsheng Pharmaceutical Co Ltd-Hunan Fangsheng Ruixin Pharmaceutical Co Ltd valued at $25.1 million, whereas the deal between Zhuhai Zhifan Enterprise Management Consulting Center-Guangzhou Mingkang Biological Engineering Co Ltd valued at $24.2 million was the fifth-largest deal.

  • Cumulatively, the top five deals amounted to $197.8 million and accounted for nearly 1.05% of the total deals (by value) announced during the last twelve months. The Asia-Pacific region accounted for 28.82% of the total Equity Offering deals done globally, and accounted for 0.34% of the total deal size on a global scale.

Asia-Pacific: Five largest Equity Offering deals by value in the Pharmaceuticals sector (LTM June 2022)

Published: June 2022
Source: GlobalData



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer